Research for Life

The Canqura patent portfolio consists of the “Killcan” family which derives from the PCT application WO 2008/063129 filed in 2007, and the “G3” EP application which derives from WO 2013/051994 filed in 2012. Both application families relate to the use of certain (nano)particles in cancer therapy. The inventions described in the two application families mainly differ in the way the (nano)particles have been defined (i.e. what they contain and their morphology).

For further detail, please refer to the attached AWA report MBS/310113

For more information on the results, tests and data please contact us